Clinical Study

A Multicenter Phase 1/2B Study Of The Bruton’S Tyrosine Kinase Inhibitor, Ibrutinib (Pci-32765), In Combination With Carfilzomib (Kyprolis™) In Subjects With Relapsed Or Relapsed And Refractory Multiple Myeloma

Posted Date: Aug 2, 2017

  • Investigator: Tahir Latif
  • Specialties: Hematology/Oncology, Oncology, Cancer
  • Type of Study: Drug

The study drug Ibrutinib (PCI-32765 or IMBRUVICA®) is a type of drug called a kinase inhibitor. Kinases are proteins that help cells live and grow. The specific kinase blocked by ibrutinib is believed to help blood cancer cells live and grow. By inhibiting the activity of this specific kinase, it is possible that ibrutinib may kill the cancer cells or stop them from growing. Ibrutinib has been approved by the U.S FDA for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia and CLL in patients with 17p deletion

Criteria:

To Be Eligible For This Study, Patients Must Have Multiple Myeloma

Keywords:

Pcyc-1119-Ca, Phase I, Cancer, Multiple Myeloma, Hematology

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.